4D Molecular Therapeutics, Inc. announced unaudited earnings results for the first quarter ended March 31, 2021. Total revenue was $2,000,000 as compared to $3,535,000 a year ago. Loss from operations was $16,312,000 as compared to $13,277,000 a year ago. Net loss and comprehensive loss was $16,406,000 as compared to $13,160,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted $0.61 against $2.54 a year ago.